JP2003514526A5 - - Google Patents

Download PDF

Info

Publication number
JP2003514526A5
JP2003514526A5 JP2001538494A JP2001538494A JP2003514526A5 JP 2003514526 A5 JP2003514526 A5 JP 2003514526A5 JP 2001538494 A JP2001538494 A JP 2001538494A JP 2001538494 A JP2001538494 A JP 2001538494A JP 2003514526 A5 JP2003514526 A5 JP 2003514526A5
Authority
JP
Japan
Prior art keywords
adenovirus
cell line
vector
amniotic
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001538494A
Other languages
English (en)
Japanese (ja)
Other versions
JP4456790B2 (ja
JP2003514526A (ja
Filing date
Publication date
Priority claimed from DE19955558A external-priority patent/DE19955558C2/de
Application filed filed Critical
Publication of JP2003514526A publication Critical patent/JP2003514526A/ja
Publication of JP2003514526A5 publication Critical patent/JP2003514526A5/ja
Application granted granted Critical
Publication of JP4456790B2 publication Critical patent/JP4456790B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2001538494A 1999-11-18 2000-11-07 永久羊膜細胞株、その生成、および遺伝子移入ベクターの生成のための使用 Expired - Lifetime JP4456790B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19955558A DE19955558C2 (de) 1999-11-18 1999-11-18 Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
DE19955558.3 1999-11-18
PCT/EP2000/010992 WO2001036615A2 (de) 1999-11-18 2000-11-07 Permanente amniozyten-zelllinie, ihre herstellung und verwendung zur herstellung von gentransfervektoren

Publications (3)

Publication Number Publication Date
JP2003514526A JP2003514526A (ja) 2003-04-22
JP2003514526A5 true JP2003514526A5 (OSRAM) 2006-02-02
JP4456790B2 JP4456790B2 (ja) 2010-04-28

Family

ID=7929523

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001538494A Expired - Lifetime JP4456790B2 (ja) 1999-11-18 2000-11-07 永久羊膜細胞株、その生成、および遺伝子移入ベクターの生成のための使用

Country Status (16)

Country Link
EP (1) EP1230354B1 (OSRAM)
JP (1) JP4456790B2 (OSRAM)
CN (1) CN100412201C (OSRAM)
AT (1) ATE257512T1 (OSRAM)
AU (1) AU784003B2 (OSRAM)
CA (1) CA2391591C (OSRAM)
CZ (1) CZ300124B6 (OSRAM)
DE (2) DE19955558C2 (OSRAM)
DK (1) DK1230354T3 (OSRAM)
ES (1) ES2211647T3 (OSRAM)
HU (1) HU227440B1 (OSRAM)
IL (2) IL149291A0 (OSRAM)
PL (1) PL205966B1 (OSRAM)
PT (1) PT1230354E (OSRAM)
TR (1) TR200400402T4 (OSRAM)
WO (1) WO2001036615A2 (OSRAM)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1528101A1 (en) * 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
JP2007522814A (ja) 2004-02-23 2007-08-16 クルセル ホランド ベー ヴェー ウイルスの精製方法
DK1869171T4 (en) 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
DE102005054628A1 (de) * 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
CA2661748C (en) 2006-08-28 2016-02-09 Alex Eon-Duval Process for the purification of fc-containing proteins
CN102203242B (zh) 2008-11-03 2013-06-12 克鲁塞尔荷兰公司 产生腺病毒载体的方法
DE102009003439A1 (de) * 2009-02-05 2010-08-26 Cevec Pharmaceuticals Gmbh Neue permanente humane Zelllinie
ES2472429T3 (es) 2009-10-15 2014-07-01 Crucell Holland B.V. Método para la purificación de partículas de adenovirus a partir de cultivos de alta densidad celular
KR101805938B1 (ko) 2009-10-15 2018-01-10 얀센 백신스 앤드 프리벤션 비.브이. 고밀도 세포 배양액에서 아데노바이러스의 정제 방법
EP2536829B1 (en) 2010-02-15 2016-04-06 Crucell Holland B.V. Method for the production of Ad26 adenoviral vectors
KR101780257B1 (ko) * 2010-08-16 2017-09-21 세벡 파마세우티컬스 게엠베하 인플루엔자 바이러스의 제조를 위한 영구 세포주
WO2013077645A1 (ko) * 2011-11-24 2013-05-30 주식회사 바이로메드 아데노바이러스 생산 신규 세포주 및 그의 용도
DK2825640T3 (en) 2012-03-12 2016-08-01 Crucell Holland Bv BATCHES OF RECOMBINANT ADENOVIRUS WITH CHANGED TERMINAL END
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
WO2013139911A1 (en) 2012-03-22 2013-09-26 Crucell Holland B.V. Vaccine against rsv
EP2662451A1 (en) * 2012-05-07 2013-11-13 Stefan Kochanek Nucleic acid construct and use of the same
EP2722337A1 (en) * 2012-10-19 2014-04-23 CEVEC Pharmaceuticals GmbH Production of a HCMV based vaccine in human amniocyte cell lines
EP2909228A1 (en) * 2012-10-19 2015-08-26 CEVEC Pharmaceuticals GmbH Production of a hcmv based vaccine in human amniocyte cell lines
ME03442B (me) 2013-04-25 2020-01-20 Janssen Vaccines & Prevention Bv Stabilizovani rastvorljivi pre-fuzioni rsv f polipeptidi
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
DE112014003136A5 (de) 2013-07-01 2016-04-21 Charité - Universitätsmedizin Berlin Immortalisierte humane Chorionzelllinie sowie Verfahren zur Immortalisierung humaner Chorionzellen
AU2015341926B2 (en) 2014-11-04 2018-09-27 Janssen Vaccines & Prevention B.V. Therapeutic HPV16 vaccines
EP3042952A1 (en) 2015-01-07 2016-07-13 CEVEC Pharmaceuticals GmbH O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
US10570417B2 (en) 2015-04-14 2020-02-25 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
EP3319633B1 (en) 2015-07-07 2020-11-11 Janssen Vaccines & Prevention B.V. Vaccine against rsv
EP3319634B1 (en) 2015-07-07 2019-08-21 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
EP3337500A1 (en) 2015-08-20 2018-06-27 Janssen Vaccines & Prevention B.V. Therapeutic hpv18 vaccines
EP3439672B1 (en) 2016-04-05 2020-11-25 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f protein for use in the prophylaxis of rsv infection
IL262109B2 (en) 2016-04-05 2023-04-01 Janssen Vaccines Prevention B V vaccine against rsv
CA3021341A1 (en) 2016-05-02 2017-11-09 Janssen Vaccine & Prevention B.V. Therapeutic hpv vaccine combinations
ES2829272T3 (es) 2016-05-12 2021-05-31 Janssen Vaccines & Prevention Bv Promotor bidireccional potente y equilibrado
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
AU2017283118B2 (en) 2016-06-20 2019-02-07 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
WO2018011196A1 (en) 2016-07-14 2018-01-18 Janssen Vaccines & Prevention B.V. Hpv vaccines
WO2018146205A1 (en) 2017-02-09 2018-08-16 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
EP3382014A1 (en) 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2019053109A1 (en) 2017-09-15 2019-03-21 Janssen Vaccines & Prevention B.V. METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV
MX2020004488A (es) 2017-10-31 2020-08-13 Janssen Vaccines & Prevention Bv Adenovirus y usos de estos.
KR20200083510A (ko) 2017-10-31 2020-07-08 얀센 백신스 앤드 프리벤션 비.브이. 아데노바이러스 및 이의 용도
KR20200077559A (ko) 2017-10-31 2020-06-30 얀센 백신스 앤드 프리벤션 비.브이. 아데노바이러스 및 이의 용도
WO2019086461A1 (en) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
MX2021005607A (es) 2018-11-13 2021-06-30 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del vrs estabilizadas.
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP3736286A1 (en) 2019-05-09 2020-11-11 Biotest AG Single chain factor viii molecule
AU2020275910A1 (en) 2019-05-15 2021-11-04 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
EP3969044A1 (en) 2019-05-15 2022-03-23 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
WO2021043757A1 (en) 2019-09-02 2021-03-11 Biotest Ag Factor viii protein with increased half-life
EP3785726A1 (en) 2019-09-02 2021-03-03 Biotest AG Factor viii protein with increased half-life
IL291852A (en) 2019-10-03 2022-06-01 Janssen Vaccines & Prevention Bv Adenovirus vectors and their use
PH12022551208A1 (en) 2019-11-18 2023-04-24 Janssen Biotech Inc Vaccines based on mutant calr and jak2 and their uses
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
CN114929261A (zh) 2020-02-17 2022-08-19 生物测试股份公司 凝血因子viii的皮下施用
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4176087A1 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
US20230024133A1 (en) 2020-07-06 2023-01-26 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
ES3035361T3 (en) 2020-10-15 2025-09-02 Hoffmann La Roche Nucleic acid constructs for va rna transcription
IL302045A (en) 2020-10-15 2023-06-01 Hoffmann La Roche Nucleic acid constructs for simultaneous gene activation
AU2022373653A1 (en) 2021-10-18 2024-05-02 Regeneron Pharmaceuticals, Inc. Eukaryotic cells comprising adenovirus-associated virus polynucleotides
EP4508241A1 (en) 2022-04-13 2025-02-19 F. Hoffmann-La Roche AG Method for determining aav genomes
JP2025517987A (ja) 2022-05-23 2025-06-12 エフ． ホフマン－ラ ロシュ アーゲー Ａａｖ粒子血清型およびａａｖ粒子負荷状態の識別のためのラマンベースの方法
CN119301260A (zh) 2022-06-03 2025-01-10 豪夫迈·罗氏有限公司 用于生产重组aav颗粒的方法
CA3261054A1 (en) 2022-07-14 2024-01-18 F. Hoffmann-La Roche Ag PROCESS FOR THE PRODUCTION OF RECOMBINANT ADENO-ASSOCIATED VIRUS PARTICLES
KR20250067819A (ko) 2022-09-12 2025-05-15 에프. 호프만-라 로슈 아게 핵산 포함 및 핵산 비포함 aav 입자를 분리하는 방법
AU2024216670A1 (en) 2023-02-07 2025-07-31 F. Hoffmann-La Roche Ag Method for the detection of anti-aav particle antibodies
KR20250162543A (ko) 2023-03-21 2025-11-18 에프. 호프만-라 로슈 아게 재조합 aav 입자 제제 생산 방법
CN117487761A (zh) * 2023-09-25 2024-02-02 南京农业大学 表达Cre基因猪骨髓巨噬细胞系的构建方法及其应用
WO2025158316A1 (en) 2024-01-26 2025-07-31 Janssen Biotech, Inc. Ovarian neoantigens and use thereof
WO2025168663A1 (en) 2024-02-09 2025-08-14 F. Hoffmann-La Roche Ag Method for producing recombinant adeno-associated viral particles
WO2025252480A1 (en) 2024-06-07 2025-12-11 F. Hoffmann-La Roche Ag Method for purifying plasmid dna

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100470180B1 (ko) * 1995-06-15 2005-02-04 크루셀 홀란드 비.브이. 유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템

Similar Documents

Publication Publication Date Title
JP2003514526A5 (OSRAM)
Parks et al. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal
Gao et al. State‐of‐the‐art human adenovirus vectorology for therapeutic approaches
Benihoud et al. Adenovirus vectors for gene delivery
Zhang et al. Role for the adenovirus IVa2 protein in packaging of viral DNA
Krasnykh et al. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism
Martin et al. TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice
JP2020022459A5 (OSRAM)
Takahashi et al. E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor
Tatsis et al. Adenoviruses as vaccine vectors
Ng et al. Development of a FLP/frt system for generating helper-dependent adenoviral vectors
JP2016501531A5 (OSRAM)
Aoki et al. Efficient generation of recombinant adenoviral vectors by Cre-lox recombination in vitro
EP0935648A4 (en) IMPROVED ADENOVIRUS VECTORS
CA2236968A1 (en) Accessory functions for use in recombinant aav virion production
WO2003092594A8 (en) Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
JP2005523730A5 (OSRAM)
CA2477954A1 (en) Means and methods for the production of adenovirus vectors
IL295858B2 (en) gRNA molecules including TRACR and crRNA, compositions containing them and their use
JP2018520648A5 (OSRAM)
EP0863202A4 (en) RECOMBINANT SENDAI VIRUS
Lusky et al. Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: requirement for E4 ORF3
Madisch et al. Phylogenetic analysis and structural predictions of human adenovirus penton proteins as a basis for tissue-specific adenovirus vector design
JP2004501650A5 (OSRAM)
CA2478616A1 (en) Use of adenoviruses mutated in the va genes for cancer treatment